BioPorto
IVD company developing NGAL biomarkers for early acute kidney injury (AKI) risk assessment.
BIOPOR | CO
Overview
Corporate Details
- ISIN(s):
- DK0011048619
- LEI:
- 5299004SWFL5JAN4W830
- Country:
- Denmark
- Address:
- Tuborg Havnevej 15, st., 2900 Hellerup
- Website:
- https://bioporto.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
BioPorto is an in-vitro diagnostics (IVD) company focused on developing and commercializing actionable biomarkers to improve patient management and outcomes. The company's core technology centers on the NGAL biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI), a condition where traditional diagnostic methods are often delayed and non-specific. Its product portfolio includes The NGAL Test™, which is CE-marked and available internationally, and ProNephro AKI (NGAL), the first FDA-cleared biomarker test for pediatric AKI risk assessment. Additionally, BioPorto provides a range of NGAL ELISA kits for preclinical and clinical research, as well as antibodies for the development of various diagnostic immunoassays.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-13 19:50 |
Share Issue/Capital Change
|
English | 12.3 KB | ||
| 2025-11-13 19:50 |
Regulatory News Service
|
Danish | 545.9 KB | ||
| 2025-11-13 19:50 |
Regulatory News Service
|
English | 511.2 KB | ||
| 2025-11-13 19:50 |
Share Issue/Capital Change
|
Danish | 12.2 KB | ||
| 2025-11-04 22:10 |
Management Discussion and Analysis
|
Danish | 225.4 KB | ||
| 2025-11-04 22:10 |
Business and Financial Review
|
English | 238.1 KB | ||
| 2025-11-04 22:10 |
Management Discussion and Analysis
|
English | 18.9 KB | ||
| 2025-11-04 22:10 |
Management Discussion and Analysis
|
Danish | 18.9 KB | ||
| 2025-11-04 22:08 |
Earnings Release
|
English | 176.7 KB | ||
| 2025-11-04 22:08 |
Earnings Release
|
Danish | 16.8 KB | ||
| 2025-11-04 22:08 |
Earnings Release
|
Danish | 161.9 KB | ||
| 2025-11-04 22:08 |
Earnings Release
|
English | 16.6 KB | ||
| 2025-11-04 22:08 |
Legal Proceedings Report
|
Danish | 170.8 KB | ||
| 2025-11-04 22:08 |
Legal Proceedings Report
|
Danish | 8.5 KB | ||
| 2025-11-04 22:08 |
Legal Proceedings Report
|
English | 181.4 KB |
Automate Your Workflow. Get a real-time feed of all BioPorto filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioPorto
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioPorto via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
